Supporters of the Board, which was created under ACA to control the growth of Medicare, have failed to grasp the greatest looming practicalconsequence: under IPAB, venture capital funding for new medical technologies and research could be drastically reduced, suffocating the innovation that has led to continued breakthroughs in the healthcare and life sciences fields.